Clinical SciencesAlphaCor™ Cases: Comparative OutcomesHicks, Celia R. FRCOphth; Crawford, Geoffrey J. FRACO; Tan, Donald T. FRCOphth; Snibson, Grant R. FRACO; Sutton, Gerard L. FRACO; Downie, Nicholas FRACO; Gondhowiardjo, Tjahjono D. MD, PhD; Lam, Dennis S.-C. FRCOphth; Werner, Liliana MD, PhD; Apple, David MD, FAOS; Constable, Ian J. FRACOAuthor Information From the Lions Eye Institute of Western Australia and Center for Ophthalmology and Visual Science (Drs Hicks, Crawford, and Constable), University of Western Australia, Australia; Singapore National Eye Center (Dr Tan), Singapore; Royal Victorian Eye and Ear Hospital (Dr Snibson), Melbourne, Australia; Sydney Eye Hospital (Dr Sutton), Sydney, Australia; Launceston General Hospital (Dr Downie), Launceston, Australia; Jakarta Eye Centre (Dr Gondhowiardjo), Jakarta, Indonesia; Hong Kong Eye Hospital (Dr Lam), Hong Kong; and Center for Research on Ocular Therapeutics and Biodevices (Drs Werner and Apple), Storm Eye Institute, Medical University of South Carolina. Supported in part by a grant from the National Health and Medical Research Council of Australia. Authors Constable, Crawford, and Hicks have proprietary interests in Argus Biomedical Pty, Ltd, the manufacturer of AlphaCor™. Reprints: C. R. Hicks, Lions Eye Institute, 2 Verdun Street, Nedlands, Western Australia 6009, Australia (e-mail: firstname.lastname@example.org). Cornea: October 2003 - Volume 22 - Issue 7 - p 583-590 Buy Abstract Purpose To describe clinical outcomes after a novel type of corneal surgery, implantation of an artificial cornea, AlphaCor™, and to evaluate outcomes in comparison with alternative keratoprostheses and high-risk grafts. Methods Case reports and data from a noncontrolled clinical trial and a literature review. Results The probability of AlphaCor retention to 1 year is 80%. Postoperative best corrected visual acuity ranges from Perception Light to 20/30. The most significant complications are stromal melts and optic depositions, for both of which the main risk factors have been identified. Complications can be managed without loss of the eye. Conclusion Results from the clinical trial period have helped to determine the indications and risk factors for AlphaCor surgery and to refine surgical techniques. Continued monitoring of outcomes as the series increases will allow a more accurate determination of comparative outcomes. The series provides preliminary evidence that AlphaCor may have a lower incidence of complications than traditional keratoprostheses and may prove to be preferable to a donor graft in high-risk cases. © 2003 Lippincott Williams & Wilkins, Inc.